| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Solid TumorSEQ™
Test Code%14340
CPT Codes
0379U<br><strong>This test is not available for Wyoming patient testing.</strong>
Preferred Specimen
1 paraffin embedded tissue block
Minimum Volume
Tissue: 1 block Unstained slides: 5 slides
Other Acceptable Specimens
10 unstained slides in slide holder
Instructions
Ship ambient or on ice pack in summer. For FFPE and slides a pathology report must be submitted with sample. Do not reject. Submit tissue in sterile biohazard plastic bag.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Acceptable
Refrigerated: Acceptable
Frozen: Unacceptable
Refrigerated: Acceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject send to laboratory for more testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
Set up: Sun, Tues, Thurs; Report available: 7-10 days
Clinical Significance
The 523-gene comprehensive genomic profiling panel is
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient's
tumor tissue. This comprehensive panel offers the
opportunity for a broader scope of genomic information
compared to single gene tests or smaller panels. For
example, it may be useful for patients with limited or
ill-defined treatment options and for those considering
clinical trials. This panel uses next-generation sequencing
to detect mutations present in DNA and RNA extracted from
formalin-fixed, paraffin embedded (FFPE) tissue sections of
solid tumors. The test is designed to detect single
nucleotide variants (SNVs) and small insertions/deletions,
as well as whole-gene copy number alterations,
translocations, and splice site variants in a select group
of genes. Microsatellite instability (MSI) and tumor
mutation burden (TMB) are also evaluated.
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient's
tumor tissue. This comprehensive panel offers the
opportunity for a broader scope of genomic information
compared to single gene tests or smaller panels. For
example, it may be useful for patients with limited or
ill-defined treatment options and for those considering
clinical trials. This panel uses next-generation sequencing
to detect mutations present in DNA and RNA extracted from
formalin-fixed, paraffin embedded (FFPE) tissue sections of
solid tumors. The test is designed to detect single
nucleotide variants (SNVs) and small insertions/deletions,
as well as whole-gene copy number alterations,
translocations, and splice site variants in a select group
of genes. Microsatellite instability (MSI) and tumor
mutation burden (TMB) are also evaluated.
